Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Public mistrust linked to drop in deceased donor organ donations and kidney transplants - 2Soldiers seize power in Guinea-Bissau and detain the president
- 3Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- 4Monetary Security: Building Serious areas of strength for an Establishment
- 5Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Indian Health Service is digging out of decades-old construction backlog for medical buildings
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- The Best Computer games for Multiplayer Fun
- Apollo vs. Artemis: What to know about NASA's return to the moon
- 21 Incredibly Interesting Contemplations To Observe Consistently
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
